Cargando…

Demography, diagnostics, and medication in dementia with Lewy bodies and Parkinson’s disease with dementia: data from the Swedish Dementia Quality Registry (SveDem)

INTRODUCTION: Whether dementia with Lewy bodies (DLB) and Parkinson’s disease with dementia (PDD) should be considered as one entity or two distinct conditions is a matter of controversy. The aim of this study was to compare the characteristics of DLB and PDD patients using data from the Swedish Dem...

Descripción completa

Detalles Bibliográficos
Autores principales: Fereshtehnejad, Seyed-Mohammad, Religa, Dorota, Westman, Eric, Aarsland, Dag, Lökk, Johan, Eriksdotter, Maria
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3700781/
https://www.ncbi.nlm.nih.gov/pubmed/23847419
http://dx.doi.org/10.2147/NDT.S45840
_version_ 1782275534577729536
author Fereshtehnejad, Seyed-Mohammad
Religa, Dorota
Westman, Eric
Aarsland, Dag
Lökk, Johan
Eriksdotter, Maria
author_facet Fereshtehnejad, Seyed-Mohammad
Religa, Dorota
Westman, Eric
Aarsland, Dag
Lökk, Johan
Eriksdotter, Maria
author_sort Fereshtehnejad, Seyed-Mohammad
collection PubMed
description INTRODUCTION: Whether dementia with Lewy bodies (DLB) and Parkinson’s disease with dementia (PDD) should be considered as one entity or two distinct conditions is a matter of controversy. The aim of this study was to compare the characteristics of DLB and PDD patients using data from the Swedish Dementia Quality Registry (SveDem). METHODS: SveDem is a national Web-based quality registry initiated to improve the quality of diagnostic workup, treatment, and care of patients with dementia across Sweden. Patients with newly diagnosed dementia of various types were registered in SveDem during the years 2007–2011. The current cross-sectional report is based on DLB (n = 487) and PDD (n = 297) patients. Demographic characteristics, diagnostic workup, Mini-Mental State Examination (MMSE) score, and medications were compared between DLB and PDD groups. RESULTS: No gender differences were observed between the two study groups (P = 0.706). PDD patients were significantly younger than DLB patients at the time of diagnosis (74.8 versus 76.8 years, respectively; P < 0.001). A significantly higher prevalence of patients with MMSE score ≤24 were found in the PDD group (75.2% versus 67.6%; P = 0.030). The mean number of performed diagnostic modalities was significantly higher in the DLB group (4.9 ± 1.7) than in the PDD group (4.1 ± 1.6; P < 0.001). DLB patients were more likely than PDD patients to be treated with cholinesterase inhibitors (odds ratio = 2.5, 95% confidence interval = 1.8–3.5), whereas the use of memantine, antidepressants, and antipsychotics did not differ between the groups. CONCLUSION: This study demonstrates several differences in the dementia work-up between DLB and PDD. The onset of dementia was significantly earlier in PDD, while treatment with cholinesterase inhibitors was more common in DLB patients. Severe cognitive impairment (MMSE score ≤24) was more frequent in the PDD group, whereas more diagnostic tests were used to confirm a DLB diagnosis. Some similarities also were found, such as gender distribution and use of memantine, antidepressants, and antipsychotics drugs. Further follow-up cost-effectiveness studies are needed to provide more evidence for workup and treatment guidelines of DLB and PDD.
format Online
Article
Text
id pubmed-3700781
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-37007812013-07-11 Demography, diagnostics, and medication in dementia with Lewy bodies and Parkinson’s disease with dementia: data from the Swedish Dementia Quality Registry (SveDem) Fereshtehnejad, Seyed-Mohammad Religa, Dorota Westman, Eric Aarsland, Dag Lökk, Johan Eriksdotter, Maria Neuropsychiatr Dis Treat Original Research INTRODUCTION: Whether dementia with Lewy bodies (DLB) and Parkinson’s disease with dementia (PDD) should be considered as one entity or two distinct conditions is a matter of controversy. The aim of this study was to compare the characteristics of DLB and PDD patients using data from the Swedish Dementia Quality Registry (SveDem). METHODS: SveDem is a national Web-based quality registry initiated to improve the quality of diagnostic workup, treatment, and care of patients with dementia across Sweden. Patients with newly diagnosed dementia of various types were registered in SveDem during the years 2007–2011. The current cross-sectional report is based on DLB (n = 487) and PDD (n = 297) patients. Demographic characteristics, diagnostic workup, Mini-Mental State Examination (MMSE) score, and medications were compared between DLB and PDD groups. RESULTS: No gender differences were observed between the two study groups (P = 0.706). PDD patients were significantly younger than DLB patients at the time of diagnosis (74.8 versus 76.8 years, respectively; P < 0.001). A significantly higher prevalence of patients with MMSE score ≤24 were found in the PDD group (75.2% versus 67.6%; P = 0.030). The mean number of performed diagnostic modalities was significantly higher in the DLB group (4.9 ± 1.7) than in the PDD group (4.1 ± 1.6; P < 0.001). DLB patients were more likely than PDD patients to be treated with cholinesterase inhibitors (odds ratio = 2.5, 95% confidence interval = 1.8–3.5), whereas the use of memantine, antidepressants, and antipsychotics did not differ between the groups. CONCLUSION: This study demonstrates several differences in the dementia work-up between DLB and PDD. The onset of dementia was significantly earlier in PDD, while treatment with cholinesterase inhibitors was more common in DLB patients. Severe cognitive impairment (MMSE score ≤24) was more frequent in the PDD group, whereas more diagnostic tests were used to confirm a DLB diagnosis. Some similarities also were found, such as gender distribution and use of memantine, antidepressants, and antipsychotics drugs. Further follow-up cost-effectiveness studies are needed to provide more evidence for workup and treatment guidelines of DLB and PDD. Dove Medical Press 2013 2013-06-28 /pmc/articles/PMC3700781/ /pubmed/23847419 http://dx.doi.org/10.2147/NDT.S45840 Text en © 2013 Fereshtehnejad et al, publisher and licensee Dove Medical Press Ltd This is an Open Access article which permits unrestricted noncommercial use, provided the original work is properly cited.
spellingShingle Original Research
Fereshtehnejad, Seyed-Mohammad
Religa, Dorota
Westman, Eric
Aarsland, Dag
Lökk, Johan
Eriksdotter, Maria
Demography, diagnostics, and medication in dementia with Lewy bodies and Parkinson’s disease with dementia: data from the Swedish Dementia Quality Registry (SveDem)
title Demography, diagnostics, and medication in dementia with Lewy bodies and Parkinson’s disease with dementia: data from the Swedish Dementia Quality Registry (SveDem)
title_full Demography, diagnostics, and medication in dementia with Lewy bodies and Parkinson’s disease with dementia: data from the Swedish Dementia Quality Registry (SveDem)
title_fullStr Demography, diagnostics, and medication in dementia with Lewy bodies and Parkinson’s disease with dementia: data from the Swedish Dementia Quality Registry (SveDem)
title_full_unstemmed Demography, diagnostics, and medication in dementia with Lewy bodies and Parkinson’s disease with dementia: data from the Swedish Dementia Quality Registry (SveDem)
title_short Demography, diagnostics, and medication in dementia with Lewy bodies and Parkinson’s disease with dementia: data from the Swedish Dementia Quality Registry (SveDem)
title_sort demography, diagnostics, and medication in dementia with lewy bodies and parkinson’s disease with dementia: data from the swedish dementia quality registry (svedem)
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3700781/
https://www.ncbi.nlm.nih.gov/pubmed/23847419
http://dx.doi.org/10.2147/NDT.S45840
work_keys_str_mv AT fereshtehnejadseyedmohammad demographydiagnosticsandmedicationindementiawithlewybodiesandparkinsonsdiseasewithdementiadatafromtheswedishdementiaqualityregistrysvedem
AT religadorota demographydiagnosticsandmedicationindementiawithlewybodiesandparkinsonsdiseasewithdementiadatafromtheswedishdementiaqualityregistrysvedem
AT westmaneric demographydiagnosticsandmedicationindementiawithlewybodiesandparkinsonsdiseasewithdementiadatafromtheswedishdementiaqualityregistrysvedem
AT aarslanddag demographydiagnosticsandmedicationindementiawithlewybodiesandparkinsonsdiseasewithdementiadatafromtheswedishdementiaqualityregistrysvedem
AT lokkjohan demographydiagnosticsandmedicationindementiawithlewybodiesandparkinsonsdiseasewithdementiadatafromtheswedishdementiaqualityregistrysvedem
AT eriksdottermaria demographydiagnosticsandmedicationindementiawithlewybodiesandparkinsonsdiseasewithdementiadatafromtheswedishdementiaqualityregistrysvedem